Associations of medication regimen complexity with copd medication adherence and control

Alex D. Federman*, Rachel O’conor, Michael S. Wolf, Juan P. Wisnivesky

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

10 Scopus citations

Abstract

Introduction: Medication adherence is often low among people with chronic obstructive pulmonary disease (COPD) and medication regimen complexity may be a contributing factor. In this study, we sought to examine the role of medication regimen complexity in COPD medication adherence among patients with multimorbidity. Methods: We performed cross-sectional analysis of data on COPD patients in primary care and pulmonary practices in New York City and Chicago (n=400). Regimen complexity was represented by the medication regimen complexity index (MRCI) and simple medication count. Adherence was measured by self-report and inhaler dose counts. Disease control measures included the COPD severity score (COPDSS) and the Medical Research Council (MRC) severity index. Results: Mean age of study participants was 69 years, 66% had MRC grades 4 or 5, and 45% had low medication adherence. MRCI scores did not differ significantly between those with and without adequate medication adherence. Patients with higher MRCI scores were more likely to have severe COPD (OR 5.00, 95% CI 1.46–17.1, p=0.01) and dyspnea grades 3 or 4 (OR 2.27, 95% CI 1.03–5.03, p=0.04). Significant associations of medication count with COPD severity were also observed. Discussion: These findings demonstrate that among patients with COPD and comorbid hypertension and diabetes, higher medication regimen complexity is associated with worse COPD control but not with COPD medication adherence.

Original languageEnglish (US)
Pages (from-to)2385-2392
Number of pages8
JournalInternational Journal of COPD
Volume16
DOIs
StatePublished - 2021

Funding

Dr. Wolf reports grants from Amgen, Eli Lilly, AbbVie, and Lundbeck, personal fees from Sanofi and Luton UK, and grants and personal fees from Pfizer and Merck, Sharpe & Dohme. Dr. Wisnivesky reports grants and personal fees from Sanofi, personal fees from Banook and Atea, and grants from Arnold. The authors report no other conflicts of interest in this work. National Heart Lung and Blood Institute, R01 HL126508.

Keywords

  • Chronic obstructive pulmonary disease
  • Medication adherence
  • Medication regimen complexity
  • Multimorbidity

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health
  • Health Policy
  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Associations of medication regimen complexity with copd medication adherence and control'. Together they form a unique fingerprint.

Cite this